(IQV) IQVIA Holdings - Overview
Sector: HealthcareIndustry: Diagnostics & Research | Exchange NYSE (USA) | Currency USD | Market Cap: 28.185m | Total Return -8.7% in 12m
Stock: Data Analytics, Clinical Trials, Healthcare Insights
Total Rating 50
Risk 81
Buy Signal -0.90
| Risk 5d forecast | |
|---|---|
| Volatility | 37.6% |
| Relative Tail Risk | -9.89% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.09 |
| Alpha | -21.02 |
| Character TTM | |
|---|---|
| Beta | 0.911 |
| Beta Downside | 0.609 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.12% |
| CAGR/Max DD | -0.13 |
EPS (Earnings per Share)
Revenue
Description: IQV IQVIA Holdings March 04, 2026
IQVIA Holdings Inc. (IQV) provides clinical research, commercial insights, and healthcare intelligence to the life sciences sector. The company operates globally, serving pharmaceutical, biotechnology, device, diagnostic, and consumer health companies. The life sciences tools and services industry is critical for drug development and market analysis.
The companys operations are divided into three segments. Technology & Analytics Solutions offers cloud-based applications, real-world data solutions, and consulting services. This segment also provides detailed pharmaceutical sales and prescribing trend data. The Research & Development Solutions segment focuses on clinical trial management, monitoring, and laboratory services, essential for bringing new therapies to market. Contract Sales & Medical Solutions provides healthcare provider and patient engagement, alongside scientific and medical strategy support.
For more detailed financial and operational data, consider exploring ValueRay.
Headlines to watch out for
- R&D Solutions demand drives clinical trial revenue
- Technology & Analytics Solutions growth boosts data sales
- Healthcare industry spending impacts service demand
- Regulatory changes influence drug development costs
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 1.36b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.42 > 1.0 |
| NWC/Revenue: -12.81% < 20% (prev -7.32%; Δ -5.49% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.65b > Net Income 1.36b |
| Net Debt (14.19b) to EBITDA (3.46b): 4.10 < 3 |
| Current Ratio: 0.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (171.9m) vs 12m ago -4.92% < -2% |
| Gross Margin: 26.28% > 18% (prev 0.33%; Δ 2.59k% > 0.5%) |
| Asset Turnover: 57.39% > 50% (prev 57.27%; Δ 0.12% > 0%) |
| Interest Coverage Ratio: 3.18 > 6 (EBITDA TTM 3.46b / Interest Expense TTM 729.0m) |
Altman Z'' 1.70
| A: -0.07 (Total Current Assets 6.25b - Total Current Liabilities 8.34b) / Total Assets 29.94b |
| B: 0.25 (Retained Earnings 7.42b / Total Assets 29.94b) |
| C: 0.08 (EBIT TTM 2.32b / Avg Total Assets 28.42b) |
| D: 0.77 (Book Value of Equity 17.86b / Total Liabilities 23.31b) |
| Altman-Z'' Score: 1.70 = BBB |
Beneish M -2.79
| DSRI: 1.00 (Receivables 3.43b/3.24b, Revenue 16.31b/15.40b) |
| GMI: 1.26 (GM 26.28% / 33.15%) |
| AQI: 1.01 (AQ_t 0.76 / AQ_t-1 0.75) |
| SGI: 1.06 (Revenue 16.31b / 15.40b) |
| TATA: -0.04 (NI 1.36b - CFO 2.65b) / TA 29.94b) |
| Beneish M-Score: -2.79 (Cap -4..+1) = A |
What is the price of IQV shares?
As of March 28, 2026, the stock is trading at USD 163.85 with a total of 1,526,946 shares traded.
Over the past week, the price has changed by -1.34%, over one month by -8.37%, over three months by -27.85% and over the past year by -8.65%.
Over the past week, the price has changed by -1.34%, over one month by -8.37%, over three months by -27.85% and over the past year by -8.65%.
Is IQV a buy, sell or hold?
IQVIA Holdings has received a consensus analysts rating of 4.30.
Therefore, it is recommended to buy IQV.
- StrongBuy: 14
- Buy: 2
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IQV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 236.2 | 44.2% |
| Analysts Target Price | 236.2 | 44.2% |
IQV Fundamental Data Overview March 26, 2026
P/E Trailing = 21.158
P/E Forward = 13.21
P/S = 1.7281
P/B = 4.3099
P/EG = 0.9784
Revenue TTM = 16.31b USD
EBIT TTM = 2.32b USD
EBITDA TTM = 3.46b USD
Long Term Debt = 13.88b USD (from longTermDebt, last quarter)
Short Term Debt = 1.84b USD (from shortTermDebt, last quarter)
Debt = 16.17b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.19b USD (from netDebt column, last quarter)
Enterprise Value = 42.38b USD (28.19b + Debt 16.17b - CCE 1.98b)
Interest Coverage Ratio = 3.18 (Ebit TTM 2.32b / Interest Expense TTM 729.0m)
EV/FCF = 17.09x (Enterprise Value 42.38b / FCF TTM 2.48b)
FCF Yield = 5.85% (FCF TTM 2.48b / Enterprise Value 42.38b)
FCF Margin = 15.21% (FCF TTM 2.48b / Revenue TTM 16.31b)
Net Margin = 8.34% (Net Income TTM 1.36b / Revenue TTM 16.31b)
Gross Margin = 26.28% ((Revenue TTM 16.31b - Cost of Revenue TTM 12.02b) / Revenue TTM)
Gross Margin QoQ = 6.69% (prev 33.49%)
Tobins Q-Ratio = 1.42 (Enterprise Value 42.38b / Total Assets 29.94b)
Interest Expense / Debt = 1.19% (Interest Expense 193.0m / Debt 16.17b)
Taxrate = 10.14% (58.0m / 572.0m)
NOPAT = 2.08b (EBIT 2.32b * (1 - 10.14%))
Current Ratio = 0.75 (Total Current Assets 6.25b / Total Current Liabilities 8.34b)
Debt / Equity = 2.49 (Debt 16.17b / totalStockholderEquity, last quarter 6.50b)
Debt / EBITDA = 4.10 (Net Debt 14.19b / EBITDA 3.46b)
Debt / FCF = 5.72 (Net Debt 14.19b / FCF TTM 2.48b)
Total Stockholder Equity = 6.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.79% (Net Income 1.36b / Total Assets 29.94b)
RoE = 22.28% (Net Income TTM 1.36b / Total Stockholder Equity 6.10b)
RoCE = 11.61% (EBIT 2.32b / Capital Employed (Equity 6.10b + L.T.Debt 13.88b))
RoIC = 9.82% (NOPAT 2.08b / Invested Capital 21.23b)
WACC = 6.23% (E(28.19b)/V(44.36b) * Re(9.19%) + D(16.17b)/V(44.36b) * Rd(1.19%) * (1-Tc(0.10)))
Discount Rate = 9.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.42%
[DCF] Terminal Value 86.43% ; FCFF base≈2.33b ; Y1≈2.59b ; Y5≈3.39b
[DCF] Fair Price = 466.5 (EV 92.50b - Net Debt 14.19b = Equity 78.31b / Shares 167.9m; r=6.23% [WACC]; 5y FCF grow 12.75% → 3.0% )
EPS Correlation: -11.40 | EPS CAGR: 9.07% | SUE: 0.10 | # QB: 0
Revenue Correlation: 91.62 | Revenue CAGR: 5.52% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-06-30): EPS=3.02 | Chg7d=+0.000 | Chg30d=+0.001 | Revisions Net=+2 | Analysts=20
EPS current Year (2026-12-31): EPS=12.69 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+4 | Growth EPS=+6.5% | Growth Revenue=+5.7%
EPS next Year (2027-12-31): EPS=14.06 | Chg7d=+0.000 | Chg30d=-0.019 | Revisions Net=+0 | Growth EPS=+10.8% | Growth Revenue=+5.9%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.5% (Discount Rate 9.2% - Earnings Yield 4.7%)
[Growth] Growth Spread = +1.3% (Analyst 5.8% - Implied 4.5%)
P/E Forward = 13.21
P/S = 1.7281
P/B = 4.3099
P/EG = 0.9784
Revenue TTM = 16.31b USD
EBIT TTM = 2.32b USD
EBITDA TTM = 3.46b USD
Long Term Debt = 13.88b USD (from longTermDebt, last quarter)
Short Term Debt = 1.84b USD (from shortTermDebt, last quarter)
Debt = 16.17b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.19b USD (from netDebt column, last quarter)
Enterprise Value = 42.38b USD (28.19b + Debt 16.17b - CCE 1.98b)
Interest Coverage Ratio = 3.18 (Ebit TTM 2.32b / Interest Expense TTM 729.0m)
EV/FCF = 17.09x (Enterprise Value 42.38b / FCF TTM 2.48b)
FCF Yield = 5.85% (FCF TTM 2.48b / Enterprise Value 42.38b)
FCF Margin = 15.21% (FCF TTM 2.48b / Revenue TTM 16.31b)
Net Margin = 8.34% (Net Income TTM 1.36b / Revenue TTM 16.31b)
Gross Margin = 26.28% ((Revenue TTM 16.31b - Cost of Revenue TTM 12.02b) / Revenue TTM)
Gross Margin QoQ = 6.69% (prev 33.49%)
Tobins Q-Ratio = 1.42 (Enterprise Value 42.38b / Total Assets 29.94b)
Interest Expense / Debt = 1.19% (Interest Expense 193.0m / Debt 16.17b)
Taxrate = 10.14% (58.0m / 572.0m)
NOPAT = 2.08b (EBIT 2.32b * (1 - 10.14%))
Current Ratio = 0.75 (Total Current Assets 6.25b / Total Current Liabilities 8.34b)
Debt / Equity = 2.49 (Debt 16.17b / totalStockholderEquity, last quarter 6.50b)
Debt / EBITDA = 4.10 (Net Debt 14.19b / EBITDA 3.46b)
Debt / FCF = 5.72 (Net Debt 14.19b / FCF TTM 2.48b)
Total Stockholder Equity = 6.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.79% (Net Income 1.36b / Total Assets 29.94b)
RoE = 22.28% (Net Income TTM 1.36b / Total Stockholder Equity 6.10b)
RoCE = 11.61% (EBIT 2.32b / Capital Employed (Equity 6.10b + L.T.Debt 13.88b))
RoIC = 9.82% (NOPAT 2.08b / Invested Capital 21.23b)
WACC = 6.23% (E(28.19b)/V(44.36b) * Re(9.19%) + D(16.17b)/V(44.36b) * Rd(1.19%) * (1-Tc(0.10)))
Discount Rate = 9.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.42%
[DCF] Terminal Value 86.43% ; FCFF base≈2.33b ; Y1≈2.59b ; Y5≈3.39b
[DCF] Fair Price = 466.5 (EV 92.50b - Net Debt 14.19b = Equity 78.31b / Shares 167.9m; r=6.23% [WACC]; 5y FCF grow 12.75% → 3.0% )
EPS Correlation: -11.40 | EPS CAGR: 9.07% | SUE: 0.10 | # QB: 0
Revenue Correlation: 91.62 | Revenue CAGR: 5.52% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-06-30): EPS=3.02 | Chg7d=+0.000 | Chg30d=+0.001 | Revisions Net=+2 | Analysts=20
EPS current Year (2026-12-31): EPS=12.69 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+4 | Growth EPS=+6.5% | Growth Revenue=+5.7%
EPS next Year (2027-12-31): EPS=14.06 | Chg7d=+0.000 | Chg30d=-0.019 | Revisions Net=+0 | Growth EPS=+10.8% | Growth Revenue=+5.9%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.5% (Discount Rate 9.2% - Earnings Yield 4.7%)
[Growth] Growth Spread = +1.3% (Analyst 5.8% - Implied 4.5%)